Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 3Phase 2 2Phase 1/2 1

Status

Completed 7Active not recruiting 5Terminated 2Recruiting 2Withdrawn 1Unknown 1Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Breast 1

Conditions

Inflammatory Breast Neoplasms 1Hemangiosarcoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × talimogene laherparepvec × Clear all
NCT02658812 2023-01-25

Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery

M.D. Anderson Cancer Center

Phase 2 Terminated
11 enrolled 16 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT03921073 2022-11-01

Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
5 enrolled 5 charts
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡